[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642150":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":26,"locations":32,"responsibleParty":48,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":65,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":77,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ketamine Treated Cohort",null,"Observational cohort of patients who received ketamine infusion therapy for the treatment of chronic pain",[13],"Drug: Ketamine (Ketalar)",{"label":15,"type":10,"description":16,"interventionNames":10},"Denied Treatment Cohort","Observational cohort of patients who were recommended ketamine infusion therapy but did not receive this treatment due to lack of insurance coverage",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Ketamine (Ketalar)","Intravenous ketamine infusion delivered as part of routine clinical care",[9],[24,25],"Ketamine Infusion","Intravenous Ketamine",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Protocol Director","CONTACT","650-264-9442","tlii@stanford.edu",[33],{"facility":34,"status":10,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Stanford Health Care","Stanford","California","94305","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-122.16608,37.42411,{"lat":44,"lon":43},[47],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Theresa Lii","Instructor","100642150","outcomes-registry-after-ketamine-infusions-for-chronic-pain-a-longitudinal-evaluation-100642150",false,"NCT07648771","Outcomes Registry After Ketamine Infusions for Chronic Pain: A Longitudinal Evaluation","Nationwide Observational Registry of Patient Outcomes Following Ketamine Infusion Therapy for Chronic Pain","ORACLE","Inclusion Criteria:\n\n* Planning to receive an intravenous ketamine infusion for the treatment of chronic pain\n\nExclusion Criteria:\n\n* Unable to read or understand English questionnaires","ALL","18 Years",{"count":63,"type":64},800,"ESTIMATED","16 Weeks","OBSERVATIONAL","Ketamine is an anesthetic drug that is sometimes used to relieve chronic pain. The goal of this observational study is to learn about how patients respond to ketamine infusions for chronic pain.\n\nNote: This study does not provide ketamine - instead, this study uses surveys to follow patients who are already scheduled to receive ketamine infusions as part of their regular medical care.\n\nWe will also follow a second group of patients who were recommended ketamine infusions by their doctor but were denied insurance coverage for this treatment. These participants will complete the same surveys for up to 16 weeks, starting from when their treatment was originally scheduled. Comparing this group to patients who received ketamine will help researchers better understand ketamine's effects and how insurance denials affect chronic pain patients.",[69,70],"Chronic Pain","Ketamine",[72,73,74,75,70,69,76],"Observational","Registry","Longitudinal","Surveys","Analgesia","NOT_YET_RECRUITING","2026-06-12",{"date":80,"type":81},"2026-06-15","ACTUAL",{"date":83,"type":64},"2026-08",{"date":85,"type":64},"2034-12",{"name":5,"class":6},1]